S

Synthaverse SA
WSE:SVE

Watchlist Manager
Synthaverse SA
WSE:SVE
Watchlist
Price: 4.14 PLN -2.47% Market Closed
Market Cap: 293m PLN
Have any thoughts about
Synthaverse SA?
Write Note

Gross Margin
Synthaverse SA

60.7%
Current
56%
Average
63.9%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
60.7%
=
Gross Profit
34.8m
/
Revenue
57.4m

Gross Margin Across Competitors

Country Company Market Cap Gross
Margin
PL
Synthaverse SA
WSE:SVE
292m PLN
61%
FR
Pharnext SCA
OTC:PNEXF
6T USD
0%
US
Abbvie Inc
NYSE:ABBV
314.9B USD
67%
US
Amgen Inc
NASDAQ:AMGN
140.6B USD
60%
US
Gilead Sciences Inc
NASDAQ:GILD
115.7B USD
78%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
103.9B USD
86%
US
Epizyme Inc
F:EPE
94.1B EUR
76%
AU
CSL Ltd
ASX:CSL
135.7B AUD
52%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.8B USD
87%
US
Seagen Inc
F:SGT
39.3B EUR
75%
NL
argenx SE
XBRU:ARGX
36B EUR
89%
Country PL
Market Cap 292m PLN
Gross Margin
61%
Country FR
Market Cap 6T USD
Gross Margin
0%
Country US
Market Cap 314.9B USD
Gross Margin
67%
Country US
Market Cap 140.6B USD
Gross Margin
60%
Country US
Market Cap 115.7B USD
Gross Margin
78%
Country US
Market Cap 103.9B USD
Gross Margin
86%
Country US
Market Cap 94.1B EUR
Gross Margin
76%
Country AU
Market Cap 135.7B AUD
Gross Margin
52%
Country US
Market Cap 77.8B USD
Gross Margin
87%
Country US
Market Cap 39.3B EUR
Gross Margin
75%
Country NL
Market Cap 36B EUR
Gross Margin
89%
No Stocks Found

Synthaverse SA
Glance View

Market Cap
292m PLN
Industry
Biotechnology

Biomed Lublin Wytwornia Surowic i Szczepionek SA engages in the manufacture of pharmaceutical products. The company is headquartered in Lublin, Woj. Lubelskie and currently employs 234 full-time employees. The company went IPO on 2011-07-29. The firm focuses on the production of drugs in the field of immunotherapy. Synthaverse SA offers its services in the field such as: oncological immunotherapy, Immunotherapy in Serological Conflict, Passive immunotherapy in hepatitis B, Active anti-tuberculosis immunotherapy, Gynecology and Proctology, Probiotics, Laboratory reagents. The firm offers injection drugs, lyophilisates of active substances in sterile sealed vials, active substances and drugs based on surface and submerged biological culture, suppository forms of drugs. The firm supplies its products to 50 countries around the world.

SVE Intrinsic Value
6.95 PLN
Undervaluation 40%
Intrinsic Value
Price
S

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
60.7%
=
Gross Profit
34.8m
/
Revenue
57.4m
What is the Gross Margin of Synthaverse SA?

Based on Synthaverse SA's most recent financial statements, the company has Gross Margin of 60.7%.